NASDAQ:VIR
Biopharma Partnership: Astellas and Vir Bio Collaborate on Precision Oncology
Astellas Pharma and Vir Biotechnology just announced a global strategic collaboration. The deal centers on VIR-5500, an investigational T-cell engager (TCE) for prostate cancer. I’m looking at the financial terms—it’s a massive commitment. Vir is receiving $335 million upfront with a total deal value potentially hitting $1.7 billion. I see a clear signal here: the…
